Valeant, the acquisitive speciality pharma company, recently turned its sights on US drugmaker Cephalon, with a $5.7bn hostile offer to acquire the biotech company. Unsatisfied with the speed at which the Cephalon board was responding, Valeant Chief Executive Mike Pearson has taken the offer directly to the shareholders with an all-cash deal
Produced by Christopher Booker
Welcome to the new FT.com.
The same global insight. Faster than ever before on all your devices.